Anthem Biosciences Limited has announced its quarterly earnings conference call to discuss Q3FY26 financial results. The company has scheduled the call for February 05, 2026, providing investors and analysts an opportunity to review its performance for the quarter ended December 31, 2025.

Conference Call Details

The earnings call is scheduled for Thursday, February 05, 2026, at 02:30 PM IST. The company has coordinated with multiple time zones to accommodate international participants, with the call timing set at 04:00 AM USA time, 09:00 AM UK time, and 05:00 PM Singapore/Hong Kong time.

Key Participants

The conference call will feature senior management from Anthem Biosciences, providing insights into the company's quarterly performance and business developments.

Company Representatives:

• Mr. Ajay Bhardwaj - Managing Director and Chief Executive Officer
• Mr. Gawir Baig - Chief Financial Officer

Participation Details

JM Financial Institutional Securities Limited is hosting the earnings call and has provided comprehensive dial-in information for participants. The company recommends dialing in 10 minutes prior to the scheduled time to ensure proper connection.

Dial-in Information

Financial Results Coverage

The conference call will focus on discussing the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. This represents the company's Q3FY26 performance, providing stakeholders with detailed insights into operational and financial metrics.

Regulatory Compliance

The announcement has been made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has informed both BSE Limited and National Stock Exchange of India Limited about the scheduled earnings call, ensuring compliance with disclosure requirements.

Anthem Biosciences Limited has issued corporate guarantees totaling ₹49.00 crores to facilitate working capital credit facilities for its wholly owned subsidiary, Neoanthem Lifesciences Private Limited. The company informed stock exchanges about this development on January 07, 2026, under Regulation 30 of SEBI LODR Regulations.

Guarantee Structure and Banking Partners

The corporate guarantees have been structured across two major banking institutions to support Neoanthem's operational funding requirements:

These guarantees serve as security for various fund-based working capital credit facilities sanctioned by the respective lenders for Neoanthem Lifesciences Private Limited.

Transaction Details and Terms

The corporate guarantee arrangement includes several key operational parameters. The funds from these credit facilities will be exclusively utilized for meeting the working capital requirements of Neoanthem. The guarantees will remain in force until the full and final payment of all obligations to the lenders' satisfaction.

Anthem Biosciences has confirmed that promoters, promoter groups, and group companies have no direct interest in this transaction, and the corporate guarantee has been issued on an arm's length basis.

Financial Impact Assessment

The company has provided a clear assessment of the financial implications of these guarantees:

Regulatory Compliance

Anthem Biosciences has fulfilled its disclosure obligations by informing both major stock exchanges about this corporate guarantee issuance. The company submitted the required intimation to BSE Limited and National Stock Exchange of India Limited, providing comprehensive details as mandated under SEBI regulations.

The disclosure includes all necessary information as per Regulation 30 of SEBI LODR Regulations and SEBI Master Circular dated November 11, 2024. Complete details of the transaction have also been made available on the company's official website for investor access.